FAKTOR OPTIONSSCHEIN - IDORSIA | Market Closed - Deutsche Boerse AG 07:51:22 24/05/2024 pm IST | ||
| 1.55 EUR | +7.64% |
|
| 1 month | -33.76% | ||
| 3 months | -98.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 1.55 | +7.64% |
| 23/24/23 | 1.44 | +2.86% |
| 22/24/22 | 1.4 | -11.95% |
| 21/24/21 | 1.59 | +2.58% |
| 17/24/17 | 1.55 | +15.67% |
Delayed Quote Deutsche Boerse AG
Last update May 24, 2024 at 07:51 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | IDORSIA LTD |
| Issuer | 
BNP Paribas
|
| WKN | PN2P1D |
| ISIN | DE000PN2P1D8 |
| Date issued | 10/12/2021 |
| Strike | 2.256 CHF |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 50 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 999.8 € |
|---|---|
| Lowest since issue | 1.32 € |
| Spread | 0.01 € |
| Spread % | 0.65% |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.15
CHF
Average target price
1.692
CHF
Spread / Average Target
-21.28%
- Stock Market
- Certificates
- Certificat
